Home / Insights / Oral Film OEM vs. Private Label vs. White Label
STRIPWORKS INSIGHTS

Oral Film OEM vs. Private Label vs. White Label

What OEM, private label, white label, custom, CMO and CDMO actually mean for an oral film project, which rulebook applies, and what to write into the quote.

ANSWER IN BRIEF

The labels describe who brings the formula and who takes the risk, not a fixed service. White label is a finished product with your name on it; private label adds choices; OEM means the supplier builds to your specification; custom means the specification is developed for you. Write the responsibilities into the quote and the acronym stops mattering.

Oral film supply models compared by who brings what
ModelFormula comes fromWhat you decideDevelopment roundsPut in writing
White labelSupplier's existing stripName, artwork, countConfirmation onlyWhich formula version; change triggers
Private labelSupplier's baseFlavor, count, dose within rangeUsually oneCustomization limits; what forces new feasibility
OEMYour specificationEverything in the specDepends on spec maturityWho supplies materials, tests, signs release, holds files
CustomDeveloped for your briefActives, dose, sensory targetsTwo or moreWritten criteria; NDI check (21 CFR 190.6)
CMO / CDMOEitherCategory and rulebookVariesDrug (21 CFR 210/211) or supplement (21 CFR 111); release signatory

Why the labels confuse people

OEM, private label, white label, contract manufacturing, CMO and CDMO overlap because they come from different industries. Electronics gave us OEM, grocery gave us private label, software gave us white label, and pharma gave us CMO and CDMO. Suppliers use whichever term their last customer used. A quote that lists responsibilities and deliverables is worth more than any of the six words.

Private label and white label

White label is the narrowest: an existing finished strip, packaged under your name, with little or no change to the formula. Private label usually adds choices, such as flavor, count and sometimes dose within a proven range, plus your artwork on the sachet and carton. Both start from a concept that already sells. Melatonin strips are the clearest case: 5 mg strips in 30-count packs appear under several brands on Amazon (NuStrips, EZStrip), which is what a mature private-label category looks like.

Write the customization boundary into the proposal: which ingredients can change, by how much, and what triggers a new feasibility check. A dose change of a few milligrams may be a confirmation round; adding a second active is custom work.

OEM oral dissolving films

OEM in this category means the manufacturer produces a finished or semi-finished strip to a specification the buyer brings or approves, then hands it over for the buyer to package, market or sell. The project should state who supplies the formula sheet, raw materials, sachets, cartons and artwork; who runs the release testing; who signs the release decision; and who holds the technical files afterward.

Film physics apply regardless of who wrote the spec. Reviews put quick-release films at 2 to 8 cm2 and 20 to 70 um, with active at 5 to 30 percent of dry weight (Palezi et al., 2023). Our development targets are a 22 x 32 mm strip, 100 to 300 mg finished, up to about 250 mg single active. An OEM spec that ignores those numbers is a research project, not a production order.

Custom formulation and development

Custom begins with requirements rather than a formula: the actives and doses, film size, serving strategy, flavor, mouthfeel, dissolve target, package, market and intended claims. Feasibility (3 to 5 business days in our program) and written development criteria come before any production date. Custom also carries the one regulatory step that private label usually avoids: an ingredient without U.S. market history before October 15, 1994 needs a new dietary ingredient notification 75 days before shipment under 21 CFR 190.6.

CMO and CDMO: ask which rulebook

CMO (contract manufacturing organization) and CDMO (adds development) come from pharmaceuticals, and the oral thin film market is still mostly prescription: sublingual films took 54.7 percent of a USD 3.3 billion market in 2025, and solvent casting, the process used for most films, held 54.2 percent by technology (Mordor Intelligence). A prescription film like Suboxone, supplied 30 films per carton in child-resistant foil pouches, is made under drug rules and FDA's orally disintegrating dosage-form guidance.

A dietary supplement strip is made under 21 CFR part 111 instead. FDA's compliance guide states that contractors "must comply with those regulations directly applicable to the operations they perform," and that a distributor selling under its own label must know how the product was made in order to release it. So when a supplier says CDMO, ask three things: which product category the quote covers, which quality regulation the batch records follow, and who signs the release. An acronym is not a scope.

The comparison checklist and a worked example

Tidewell, a hydration brand, priced the same 30 mg electrolyte-and-B12 strip three ways. White label: an existing strip, Tidewell's carton, one confirmation sample, 500-box pilot of 15,000 strips at 30-count. Private label: same base with a citrus flavor and a 20-count carton, one flavor round, 10,000-strip pilot. Custom: a higher electrolyte load pushing the finished strip toward 300 mg, three formula rounds, and a longer sample phase. All three pilots ran the same release path: testing under 21 CFR 111.75, a batch record meeting 21 CFR 111.260, reserve samples at twice the test quantity under 21 CFR 111.83, and a Lot Release Packet. The difference was weeks of development and who wrote the specification, not the release standard.

Use the table to force every quote into the same shape.

Common questions

Is white label cheaper than private label?

Usually, because there is no flavor or count change to confirm, but the difference is small next to packaging minimums. Compare the total run, including testing and reserve samples, not the development line alone.

Can a supplement manufacturer call itself a CDMO?

The term is not regulated. What matters is which rulebook the batch records follow. Supplement strips fall under 21 CFR part 111; drug films fall under 21 CFR 210 and 211. Ask which one the quote covers.

Who signs the release on a private-label strip?

The manufacturer performs its release controls, but FDA's compliance guide places the decision to release under your label on the own-label distributor. Get the certificate of analysis and batch record and make that decision on paper.

Primary sources

Project-specific advice matters.

Formula feasibility, packaging, testing, claims, timing, and final quantities depend on the exact product. Use this guide to prepare better questions, then confirm the production plan for your project.

Bring the idea.
We’ll map the path.

Share your active ingredients, target dose, launch market and first-run volume. We’ll review the brief and identify the decisions needed for a pilot.

Review manufacturing capabilities · See project and quality controls

Send a project brief